ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AMRN vs BCYC // 10Y YIELD & FRED MACRO BETA

Amarin Corporation plc (NASDAQ) VS. Bicycle Therapeutics plc (NASDAQ) • 15-METRIC TALLY: AMRN 4 — BCYC 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRN VS. BCYC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AMRN BCYC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 56.60% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -12.20% -35.00% +22.80 AMRN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 2.56% — — TIE /fcf-yield <GO>
Operating Margin -23.50% -60.00% +36.50 AMRN /operating-margins <GO>
Net Profit Margin -18.20% -60.00% +41.80 AMRN /net-margins <GO>
Revenue Growth (YoY) -6.50% 105.80% -112.30 BCYC /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 2/9 +4.00 AMRN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.6 48.1 -1.42 BCYC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $262.8M $267.4M -$4.6M BCYC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AMRN REV BCYC REV AMRN GROSS % BCYC GROSS % AMRN FCF BCYC FCF
FY 2025 $213.6M $72.6M 56.6% — $6.7M -$252.0M
FY 2024 $228.6M $35.3M 35.6% — -$31.0M -$166.0M
FY 2023 $306.9M $27.0M — — $6.9M -$60.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRN // BETA —
BCYC // BETA —